& arrangement of Dhanuka laboratories limited (amalgamating company) with Orchid
As filed · Outcome of Board Meeting
GovernanceMajormateriality 80 out of 100
What happened
Fact& arrangement of Dhanuka laboratories limited (amalgamating company) with Orchid.
Why it matters
CapitSignal interpretationA qualification means the auditor could not sign off on part of the accounts, so the reported figures are not fully attested.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
DelayedEarlierFY26
We'll probably have the exact number, say, after a few months' time.
NowFY27
as our cefiderocol project will get started, say, in the next year, then we will take validation batches and hopefully, after two years, we would be able to -- once we are able to register the product from our side, we would be able to supply some percentage from our side.
Change
FactTimeline delay
Implication
CapitSignal interpretationThe earlier statement indicated that the exact capex number would be available in a few months, while the current statement suggests that the project will start next year and take two years for validation before supply can begin.
Watch next
Fact- Which line items the qualification covers
- Management's response to the qualification
- Whether it recurs in the next audited period
- Hopefully, within this quarter, we should announce one. (management committed by Q4 FY26)
- The first sales actually would be to Orchid itself internally. (management committed by Q1 FY27)
Evidence
- Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.(opens the original filing in a new tab)
- Earlier statement · FY26
- Latest statement · FY27
- Earlier statement · FY27
How CapitSignal classified this
- Reasoning:
- AUDITOR_QUALIFICATION base 80; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%